FDA’s 15-page report to the House and Senate appropriations committees was met with criticism from some leaders in the natural products and hemp industries, who have said the agency is dragging its heels on actively regulating a hemp-derived compound that has proliferated in U.S. products marketed as dietary supplements.

FDA last week told Congress it’s “actively considering potential pathways for certain CBD products to be marketed as dietary supplements” and weighing issuance of a policy related to its enforcement priorities while potentially engaging in a rulemaking process.

FDA’s 15-page report to the House and Senate appropriations committees was met with criticism from some leaders in the natural products and hemp industries, who complain the agency is dragging its heels on actively regulating CBD products.

“Historically, FDA is a slow-moving organization, such that its evaluation of FDA could extend well beyond 2020, without some form of intervention or other governmental stakeholders to expedite the process,” Garrett Graff, managing attorney at Hoban Law Group, said in an email.

Read the full article on Natural Products Insider